ER vs. IR [Design Issues]

posted by Dr_Dan  – 2019-12-19 09:01 (230 d 23:01 ago) – Posting: # 21004
Views: 1,367

Hi Helmut
your statement only holds true in your example with different strengths. If you have only one or the highest IR strength then my statement applies. The once daily (or 8 h) dosing of the ER formulation does not have to mimicry the performance of the multiple dosing of the IR formulation if you can show that there is a well-defined therapeutic window in terms of safety and efficacy and the rate of input is known not to influence the safety and efficacy profile or the risk for tolerance development.

Kind regards and have a nice day

Complete thread:

 Admin contact
20,969 posts in 4,374 threads, 1,461 registered users;
online 15 (0 registered, 15 guests [including 12 identified bots]).
Forum time: Thursday 09:02 CEST (Europe/Vienna)

It is a good morning exercise for a research scientist
to discard a pet hypothesis every day before breakfast.
It keeps him young.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz